(FBIOyF) Laboratorio de Medicina Reproductiva (LMR) - Artículo de Revista

URI permanente para esta colección

https://rephip.unr.edu.ar/handle/2133/9241

Examinar

Examinando (FBIOyF) Laboratorio de Medicina Reproductiva (LMR) - Artículo de Revista por Fecha de publicación

Filtrar resultados por año o por mes:
Mostrando 1 - 10 de 10
  • Miniatura
    ÍtemAcceso Abierto
    Preparation of monospecific anti-PAG antibodies for cattle pregnancy detection: use of synthetic peptides to improve specificity
    (SciRP, 2011-02) Ruiz Álvarez, Jimena Inés; Teijeiro, Juan Manuel; Marini, Patricia Estela
  • Miniatura
    ÍtemAcceso Abierto
  • Miniatura
    ÍtemAcceso Abierto
    Fibroblast growth factor receptors (FGFRs) in human sperm: expression, functionality and involvement in motility regulation
    (Public Library of Science (PLOS), 2015-05-13) Saucedo, Lucía; Buffa, Gabriela Natalia; Rosso, Marina; Guillardoy, Tomás; Góngora, Adrián; Munuce, María José; Vázquez Levin, Mónica Hebe; Marín Briggiler, Clara; Dr. Baldi, Alberto provide the FGF2
    Fibroblast growth factors receptors (FGFRs) have been widely characterized in somatic cells, but there is scarce evidence of their expression and function in mammalian gametes. The objective of the present study was to evaluate the expression of FGFRs in human male germ cells, to determine sperm FGFR activation by the FGF2 ligand and their participation in the regulation of sperm motility. The expression of FGFR1, 2, 3 and 4 mRNAs and proteins in human testis and localization of these receptors in germ cells of the seminiferous epithelium was demonstrated. In ejaculated sperm, FGFRs were localized to the acrosomal region and flagellum. Sperm exposure to FGF2 caused an increase in flagellar FGFR phosphorylation and activation of extracellular signal-regulated kinase (ERK) and protein kinase B (PKB or Akt) signaling pathways. Incubation with FGF2 led to a significant increase in the percentage of total and progressive sperm motility, as well as in sperm kinematics. All responses were prevented by sperm preincubation with BGJ398, a specific inhibitor of FGFR tyrosine kinase activity. In addition to confirming the expression of FGFRs in germ cells of the human testis, our study describes for the first time the presence, localization and functionality of human sperm FGFRs, and provides evidence of the beneficial effect of FGF2 upon sperm motility.
  • Miniatura
    ÍtemAcceso Abierto
    Annexin A2 and S100A10 in the mammalian oviduct
    (Springer-Verlag, 2015-09) Teijeiro, Juan Manuel; Roldán, María Lorena; Marini, Patricia Estela
  • Miniatura
    ÍtemAcceso Abierto
    Protein kinase C activity in boar sperm
    (Wiley, 2017-02-10) Teijeiro, Juan Manuel; Marini, Patricia Estela; Bragado, María Julia; García-Marin, Luis
  • Miniatura
    ÍtemAcceso Abierto
    Use of Annexin V based Sperm Selection in Assisted Reproduction
    (OMICS International, 2017-07-07) Teijeiro, Juan Manuel; Munuce, María José; Caille, Adriana María; Zumoffen, Carlos; Marini, Patricia Estela
  • Miniatura
    ÍtemAcceso Abierto
    Use of Assisted Reproduction Techniques in Male Pathologies: Molecule Based Sperm Selection Methods
    (MedCrave, 2017-08-17) Marini, Patricia Estela; Munuce, María José; Caille, Adriana María; Zumoffen, Carlos; Teijeiro, Juan Manuel
  • Miniatura
    ÍtemAcceso Abierto
    Membrane potential assessment by fluorimetry as a predictor tool of human sperm fertilizing capacity
    (Frontiers Media, 2020-01-17) Baró Graf, Carolina; Ritagliati, Carla; Torres Monserrat, Valentina; Stival, Cintia Estefanía; Carizza, Carlos; Buffone, Mariano Gabriel; Krapf, Darío
    Mammalian sperm acquire the ability to fertilize eggs by undergoing a process known as capacitation. Capacitation is triggered as the sperm travels through the female reproductive tract. This process involves specific physiological changes such as rearrangement of the cell plasma membrane, post-translational modifications of certain proteins, and changes in the cellular permeability to ions – with the subsequent impact on the plasma membrane potential (Em). Capacitation-associated Em hyperpolarization has been well studied in mouse sperm, and shown to be both necessary and sufficient to promote the acrosome reaction (AR) and fertilize the egg. However, the relevance of the sperm Em upon capacitation on human fertility has not been thoroughly characterized. Here, we performed an extensive study of the Em change during capacitation in human sperm samples using a potentiometric dye in a fluorimetric assay. Normospermic donors showed significant Em hyperpolarization after capacitation. Em values from capacitated samples correlated significantly with the sperm ability to undergo induced AR, highlighting the role of hyperpolarization in acrosomal responsiveness, and with successful in vitro fertilization (IVF) rates. These results show that Em hyperpolarization could be an indicator of human sperm fertilizing capacity, setting the basis for the use of Em values as a robust predictor of the success rate of IVF.
  • Miniatura
    ÍtemAcceso Abierto
    Standards in semen examination: publishing reproducible and reliable data based on high-quality methodology
    (NLM (Medline), 2022-08-10) Björndahl, Lars; Barratt, Christopher L.R.; Mortimer, David; Agarwal, Ashok; Aitken, Robert J.; Alvarez, Juan G.; Aneck Hahn, Natalie; Arver, Stefan; Baldi, Elisabetta; Bassas, Lluıs; Boitrelle, Florence; Bornman, Riana; Carrell, Douglas T.; Castilla, José A.; Cerezo Parra, Gerardo; Check, Jerome H.; Cuasnicu, Patricia S.; Darney, Sally Perreault; De Jager, Christiaan; De Jonge, Christopher J.; Drevet, Jöel R.; Drobnis, Erma Z.; Du Plessis, Stefan S.; Eisenberg, Michael L.; Esteves, Sandro C.; Evgeni, Evangelini A.; Ferlin, Alberto; Garrido, Nicolas; Giwercman, Aleksander; Goovaerts, Ilse G.F.; Haugen, Trine B.; Henkel, Ralf; Henningsohn, Lars; Hofmann, Marie Claude; Hotaling, James M.; Jedrzejczak, Piotr; Jouannet, Pierre; Jørgensen, Niels; Kirkman Brown, Jackson C.; Krausz, Csilla; Kurpisz, Maciej; Kvist, Ulrik; Lamb, Dolores J.; Levine, Hagai; Loveland, Kate L.; McLachlan, Robert I.; Mahran, Ali; Maree, Liana; Martins da Silva, Sarah; Mbizvo, Michael T.; Meinhardt, Andreas; Menkveld, Roelof; Mortimer, Sharon T.; Moskovtsev, Sergey; Müller, Charles H.; Munuce, María José; Muratori, Monica; Niederberger, Craig; O'Flaherty, Cristian; Oliva, Rafael; Ombelet, Willem; Pacey, Allan A.; Palladino, Michael A.; Ramasamy, Ranjith; Ramos, Liliana; Rives, Nathalie; Roldan, Eduardo Rs; Rothmann, Susan; Sakkas, Denny; Salonia, Andrea; Sánchez Pozo, Maria Cristina; Sapiro, Rosanna; Schlatt, Stefan; Schlegel, Peter N.; Schuppe, Hans Christian; Shah, Rupin; Skakkebæk, Niels E.; Teerds, Katja; Toskin, Igor; Tournaye, Herman; Turek, Paul J.; Van der Horst, Gerhard; Vazquez Levin, Monica; Wang, Christina; Wetzels, Alex; Zeginiadou, Theodosia; Zini, Armand
  • Miniatura
    ÍtemAcceso Abierto
    Factors associated with mortality among hospitalized patients with COVID-19 disease treated with convalescent plasma
    (American Society for Microbiology, 2023-11-08) Perichon, Armando M.; Acosta, Andrea; Di Tullio, Liliana; Munuce, María José; Pezzotto, Stella; Bottasso, Oscar; http://orcid.org/0000-0002-8472-7965
    The use of convalescent plasma (CP) for hospitalized patients with SARSCoV-2 infection might be a useful option in certain settings. Soon after the outbreak of COVID-19, the National Ministry of Health of Argentina recommended the use of CP transfusion for hospitalized patients with COVID-19 disease. Between 1 June and 3 October 2020, 480 patients, excluding those on invasive mechanical ventilation (IMV), received at least one CP infusion in the province of Santa Fe. We aimed to find factors associated with mortality among this cohort of patients. The median age was 60 years (interquartile range: 49–69 years) and 320 (66.7%) were males. Most of these patients (93.75%) received a single CP infusion, 82.1% and 95.6% before day 4 and day 7 of hospitalization, respectively. Anti-SARS-CoV-2 titers were determined in the CP units administered using Elecsys Anti-SARS-CoV-2 S assay. At 28 days of follow-up, 250 patients were discharged (52.1%), 131 (27.3%) remained hospitalized without and 16 (3.3%) with oxygen requirement, 27 (5.6%) were on IMV, and 56 (11.7%) had died. In the multivariate logistic regression analysis, the factors significantly associated with 28-day mortality were (i) requirement of IMV, (ii) the administration of CP after the third day of hospitalization, (iii) age, and (iv) number of comorbidities. The qualitative and quantitative analyses of antibodies against SARS-CoV-2 in the infused CP were not associated with mortality. Our findings may imply a seemingly favorable effect of CP administration among patients with severe COVID-19 disease when infused sooner after hospitalization.